Results for this period
First quarter1 February 2026 to 30 April 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Costs related to obtaining approval for partial changes to the manufacturing and marketing approval for Acugo® were the primary factor, resulting in ¥680 million in research and development expenses. Fluctuations in exchange rates resulted in ¥177 million in foreign exchange gains.
No applicable matters ("There are no applicable matters")
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 February 2026 to 30 April 2026 |
| Operating profit | △953 |
| Ordinary income | △779 |
| Profit attributable to owners of the parent | △836 |
| Net income per share | -¥10.71 |
| Equity ratio | End of the current fiscal period 85.5% / End of previous period 85.4% |
| Total assets | 14,517 Millions of yen |
| Net assets | 12,677 Millions of yen |
| Full-year earnings forecast | Net Sales 396 Millions of yen / Operating profit △5,229 / Ordinary income △5,074 / Net income △5,133 |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Segment revenue | Segment Cell therapy business using allogeneic stem cells / Net Sales Not disclosed / Year on year against the same period last year Not disclosed |
| Segment profit | Segment Cell therapy business using allogeneic stem cells / Segment profit Not disclosed / Year on year against the same period last year Not disclosed |
| Depreciation and amortization | ¥4,016 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥1,478 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Material changes No / New Not disclosed / Excluded Not disclosed / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 78,058,883 Shares |
| Treasury Shares at Period-End | 540 Shares |
| Factors Behind Changes in Business Performance | Costs related to obtaining approval for partial changes to the manufacturing and marketing approval for Acugo® were the primary factor, resulting in ¥680 million in research and development expenses. Fluctuations in exchange rates resulted in ¥177 million in foreign exchange gains. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The operating loss mainly reflected costs related to obtaining approval for partial changes to the manufacturing and marketing approval for Acugo®, including ¥680 million in research and development expenses. The reduction in the ordinary loss and net loss was attributable to ¥177 million in foreign exchange gains arising from fluctuations in exchange rates.